



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



Saroglitazar magnesium

Cat. No.:	HY-19937A
CAS No.:	1639792-20-3
Molecular Formula:	C ₅₀ H ₅₆ MgN ₂ O ₈ S ₂
Molecular Weight:	901.42
Target:	PPAR
Pathway:	Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 125 mg/mL (138.67 mM; Need ultrasonic)				
	Preparing Stock Solutions	<div>Solvent Concentration</div> <div>Mass</div>	1 mg	5 mg	10 mg
		1 mM	1.1094 mL	5.5468 mL	11.0936 mL
		5 mM	0.2219 mL	1.1094 mL	2.2187 mL
		10 mM	0.1109 mL	0.5547 mL	1.1094 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.75 mg/mL (3.05 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.75 mg/mL (3.05 mM); Suspended solution; Need ultrasonic				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.75 mg/mL (3.05 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	Saroglitazar magnesium is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC ₅₀ values of 0.65 pM and 3 nM in HepG2 cells, respectively.	
IC ₅₀ & Target	PPARα 0.65 pM (EC ₅₀ , HepG2 cell)	PPARγ 3 nM (EC ₅₀ , HepG2 cell)
In Vivo	In db/db mice, 12-day treatment with Saroglitazar (0.01-3 mg/kg per day, orally) causes dose-dependent reductions in serum triglycerides (TG), free fatty acids (FFA), and glucose. The ED ₅₀ for these effects is found to be 0.05, 0.19, and 0.19	

mg/kg, respectively with AUC-glucose following oral glucose administration (59%) at 1 mg/kg dose. A 90-day repeated dose comparative study in Wistar rats and marmosets confirms efficacy (TG lowering) potential of Saroglitazar and has indicated low risk of PPAR-associated side effects in humans. Based on efficacy and safety profile, Saroglitazar appears to have good potential as novel therapeutic agent for treatment of dyslipidemia and diabetes^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Animal Administration ^[1]

Rats: Rats randomize based on body weights and are divided into three equal groups and receives the daily administration of vehicle (50% w/v honey for marmoset and 0.1% carboxymethylcellulose for Wistar rats) or Saroglitazar (1.5 and 15 mg/kg per day) for 90 days by oral gavage^[1].

Mice: Male C57BL/6J-db/db mice are bled on day 0 to determine pretreatment serum glucose and TG. During next 12 days, each animal is dosed (by oral gavage) with vehicle (0.5% sodium carboxymethyl cellulose) or Saroglitazar (0.01, 0.03, 0.1, 0.3, 1, and 3 mg/kg per day) or U 72107 (60 mg/kg per day) and on day 12 of the treatment, blood samples are collected (1 h after dosing) from orbital sinus under light ether anesthesia. The serum is isolated and analyzed for glucose, TG, and free fatty acid (FFA)^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Cell Biol Toxicol. 2020 Jul 1.
- BMC Complement Med Ther. 2021 Apr 10;21(1):118.
- Patent. US20210275504A1.
- Patent. US20190388398A1.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Jain MR, et al. Saroglitazar, a novel PPAR α / γ agonist with predominant PPAR α activity, shows lipid-lowering effects in preclinical models. Pharmacol Res Perspect. 2015 Jun;3(3):e00136.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA